Respiratory-chain diseases related to complex III deficiency  by Bénit, Paule et al.
Biochimica et Biophysica Acta 1793 (2009) 181–185
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrReview
Respiratory-chain diseases related to complex III deﬁciency
Paule Bénit, Sophie Lebon, Pierre Rustin ⁎
Inserm, U676, Hôpital Robert Debré, Paris, F-75019, France
Université Paris 7, Faculté de Médecine Denis Diderot, IFR02, Paris, France⁎ Corresponding author. Inserm U676, Hôpital Robert D
Sérurier, 75019 Paris, France. Tel.: +33 1 40 03 19 89; fax
E-mail address: pierre.rustin@inserm.fr (P. Rustin).
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.06.004a b s t r a c ta r t i c l e i n f oArticle history: Complex III deﬁciencies are
Received 22 February 2008
Received in revised form 27 May 2008
Accepted 4 June 2008
Available online 13 June 2008
Keywords:
Human OXPHOS disease
Mitochondria
Complex III
BC1 complex
BCS1L
QP-C
Cytochrome bamong the least common respiratory-chain abnormalities identiﬁed to date in
humans. Nevertheless, their unexplained tissue speciﬁcity and broad clinical spectrum make them a valuable
model for investigating respiratory-chain diseases. In this review, we brieﬂy discuss the properties of
complex III and the assay conditions relevant to the screening of high-risk patients. We then review the most
recent advances in the ﬁeld, which include the characterization of several disease genes and of the
corresponding clinical presentations. Finally, we discuss genetic and biochemical aspects that may help to
understand complex III-associated diseases.
© 2008 Elsevier B.V. All rights reserved.1. Complex IIIThe mammalian mitochondrial complex III (bc1 complex; ubiqui-
nol cytochrome c reductase; EC 1.10.2.2) monomer contains up to 11
subunits (heart, liver), of which only one, cytochrome b, is encoded by
themitochondrial genome [1]. In its native form, complex III is dimeric,
being closely associated in varying proportions with complexes I and
IV to form the respirasome [2]. Respirasome formation impacts
reaction kinetics in the respiratory chain and has major physiological
consequences [3]. A study of yeast mutants with deletions of genes for
one ormore complex III subunits showed that a subcomplex consisting
of cytochrome b, subunit 7, and subunit 8 was apparently associated
with cytochrome c oxidase early in the assembly process, prior to
acquisition of the remaining cytochrome bc1 subunits [4]. An
additional subcomplex consisted of subunit 9 and the Rieske protein,
and there were two subcomplexes containing cytochrome c1 asso-
ciated with core protein 1 and core protein 2, respectively. These data
strongly suggest that respirasome assembly should be studied as a
whole, rather than as a step-by-step process involving the addition of
one respiratory-chain complex after the other. In keeping with this,
respiratory-chain complexes were deﬁned chieﬂy based on technicalebré, Bât. Ecran, 48, Boulevard
: +33 1 40 03 19 78.
l rights reserved.considerations, i.e., isolation procedures and identiﬁcation of speciﬁc
electron donor and acceptor couples allowing for the measurement of
an electron ﬂow through each complex [5].
In the respiratory chain, the various dehydrogenases reduce a
fraction of the mitochondrial ubiquinone pool to ubiquinol, which, in
turn, is oxidized by complex III at the Qo (or Qp) site (Fig. 1A). Then,
complex III oxidizes ubiquinol at the membrane phase and reduces
cytochrome c at the outer surface of the inner membrane, producing a
semi-quinone, which is further oxidized by cytochrome b species,
a process known as the Q cycle [6].
Complex III uses the released energy for vectorial translocation of two
protons (H+/QH2) from the matrix to the intermembrane space, where it
releases twoadditional protons (scalar;H+/QH2) [7]. Asmentionedabove,
semi-reduced forms of ubiquinone participate in the electron/proton
transfer catalyzed by complex III. These semi-quinones are particularly
prone to autooxidation, which produces superoxides (as does reduced
cytochrome b) [8,9]. Accordingly, reduced complex III is one of the major
sites of superoxide production in the respiratory chain [10].
2. Measuring complex III in human samples
Assessing respiratory-chain enzyme activities in human samples is
difﬁcult, both because the amount of available tissue/cells is usually
Fig. 1. Complex III and measurement of its activity. (A) Diagram of electron and proton ﬂuxes through respiratory-chain complex III showing the dehydrogenase-associated
ubiquinone pools (each having distinct kinetics and a speciﬁc dehydrogenase for reduction) and the sites of inhibition by antimycin and myxothiazol. (B) left panel, typical
spectrophotometric recording at 550 minus 540 nm of cytochrome c reduction triggered by decylubiquinol using 2 µl of human liver homogenate (10 mg of tissue homogenized in
40 µl of Tris buffer [20 mM; pH 7.2] containing 0.25 M sucrose, 40 mM KCl, 2 mM EGTA, and 1 mg/ml bovine serum albumin, using a 100-µl glass potter; central panel, chemicals and
concentrations used for assaying complex III; right panel, diagram of the antimycin-sensitive electron ﬂow between decylubiquinol and cytochrome cmeasured during the assay of
complex III. Decylubiquinol can be prepared from commercially available decylubiquinone. In brief, 25 mg of decylubiquinone is solubilized with 2.5 ml dimethyl sulfoxide (DMSO).
While stirring magnetically, 450 µl of acidiﬁed water (400 µl H2O+50 µl HCl 0.1 N) is added. Then, a very large excess of dithionite (sodium hydrosulﬁte) is added gradually. The
initially yellow solution/suspension gradually becomes transparent. When the solution is colourless, the excess dithionite is allowed to deposit and the supernatant is introduced in
1.5-ml centrifugation tubes. After centrifugation for 5 min at 10,000 rpm, the supernatants are collected and stirred for 10 min. All the steps are carried out under a chemical hood.
Small samples (less than 50 µl) are stored at −80 °C. Upon thawing, carefully re-suspend the crystal that usually forms at the bottom of the tube. BSA, bovine serum albumin; Cyt c,
cytochrome c; Dh, respiratory-chain dehydrogenases; DQH2, decylubiquinol; Qo (or Qp); Qi (or Qn): quinone-binding sites on the outer (Qo) or inner (Qi) surface of the membrane,
respectively; S, sample; I, III, IV, and V: the respiratory-chain complexes.
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fractions [11]. As a result, partial complex III deﬁciencies are easily
missed [12]. Complex III activity is easily measured by spectro-
photometric monitoring of the antimycin-sensitive reduction of
cytochrome c at 550 nm (Fig. 1B). The Km of complex III for
cytochrome c is relatively high (N5 µM) and cytochrome c may
become rapidly limiting for complex III activity measured using this
assay [12]. Reduction of cytochrome c is triggered by adding a reduced
ubiquinone analogue in the presence of cyanide, e.g., decylubiquinol,
whose preparation is described in detail in the legend of Fig. 1B [13].
Several interfering reactions (non-enzymatic redox reactions
involving quinols, bovine serum albumin, and cytochrome c) can
occur when measuring complex III activity. These reactions have been
studied in detail [12] and taken into account to develop a convenient
assay for measuring complex III [11]. The use of an alkyl glycoside
detergent, such as lauryl maltoside, keeps these interfering reactions
at an acceptably low level (75–95% of antimycin sensitivity). Finally,complex III gradually loses its activity if the biological samples are not
properly stored. In human liver, heart homogenates, and cultured
ﬁbroblasts, the loss of complex III activity follows the loss of quinone
pool-dependent activities (i.e., succinate cytochrome c reductase) and
complex I activity [13]. Extracts should not be kept more than 1 h
(at ice melting temperature) before complex III measurement.
2.1. Disease genes
Mutations in one mitochondrial gene (for cytochrome b) and two
nuclear genes encoding complex III subunits have been shown to
cause human disease.
2.2. Mitochondrial gene: cytochrome b
A number of mutations have been reported in the cytochrome b
gene, including frameshift and termination mutations, deletions, and
Fig. 2. Cytochrome b mutations associated with human disease. Location of mutations (italics; according to [15]) in a bi-dimensional model for the cytochrome b protein structure.
Note that most of the trans-membrane domains (A–H) are free from mutations.
Fig. 3. Complex III deﬁciency in humans. Organ/system involvement in patients
harboring mutations in mitochondrial and nuclear genes (cytochrome b, BCS1L, QP-C)
encoding complex III subunits.
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the trans-membrane domains (Fig. 2) [14]. As with any mutation
affecting the mitochondrial genome, demonstrating a deleterious
effect is challenging. Although nonsense and frameshift mutations
resulting in truncated cytochrome b proteins can be expected to exert
deleterious effects, other mutations may be polymorphisms that are
frequently encountered in the mitochondrial genome [15]. Studies
of mutant yeast have shown that the deleterious effect of a given
mutation can target the catalytic activity and/or the assembly of
complex III (truncating mutations). The considerable similarity
between yeast and human cytochrome b has prompted extensive use
of yeast to establish or dismiss deleterious effects of humanmutations.
Accordingly several human mutations (e.g. G34S, G339E, G290D) are
believed to cause disease, as targeting their counterpart in yeast
abolishes complex III assembly or activity [14]. A number of other
mutations (e.g. D171N) are probably deleterious, given that alterations
at the site of the corresponding amino acid would be expected to
impair the activity of complex III. Other base changes (L236I, V356M)
probably have little or no effect. Information on deleterious cyto-
chrome b mutations is regularly updated and made available through
the Internet [15]. Interestingly, there have been a few reports of
complex I deﬁciency in patients with cytochrome b mutations
responsible for complex III deﬁciency [16] and of complex III deﬁciency
in patients with mutations in the nuclear complex I gene [17]. These
combinations strongly suggest a structural relationship between
complexes III and I and are consistent with the occurrence in the
respiratory chain of one or more supercomplex(es) in which
cytochrome b plays a key role [16]. However, most of the mutations
that affect complex III components, including cytochrome b, do not
impair complex I activity; and complex III function is normal in most
carriers of mutations in genes encoding complex I subunits [18,19].
Although these data are somewhat difﬁcult to reconcile, they suggest
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or cell. Alternatively, speciﬁc alterations may be associated with a
subset of mutant proteins.
The main clinical presentations associated with cytochrome b
mutations (Fig. 3) are similar to those seen with mutations affecting
other respiratory-chain complexes, although the frequency distribution
of clinical manifestations varies according to the complex involved [20].
In particular, cytochrome b mutations have been identiﬁed in patients
affected by the Leber Hereditary Optic Neuropathy (LHON), speciﬁcally
targeting the optic tract. So far the variety of clinical presentations
associatedwith cytochrome bmutations remains largely unexplained. In
a given individual, organ-to-organ variations in the ratio of mutant to
wild-typemitochondrial DNA (heteroplasmy) associatedwith variations
in tissue sensitivity to respiratory-chain defects may be involved [21].
However, to explain the features encountered in large numbers of
patients, the involvement of other factors must be assumed. We know
little about the complex relationships between mitochondria and their
host cells,which involve thousands of proteins and factors determined in
part by the genetic background of each individual [22]. The increasing
number of mitochondrial DNA variants described as modifying the
expression of themutantmitochondrial genotype or as constituting risk
factors for human disease or sensitivity to environmental agents (e.g.,
aminoglycosides) illustrates the major impact of the individual genetic
background on the function of the mitochondrial genome [23,24].
Shaping and maintaining the respiratory chain, handling oxygen and
nitrogen radical species, and performing other mitochondrial functions
require the involvement of myriad proteins, whose properties and
activity levelsmaymodulate susceptibility tomitochondrial dysfunction.
Cytochrome b mutations have been identiﬁed not only in patients
having a spectrum of clinical manifestations typical for mitochondrial
disease, but also in patients with cancer at various sites (breast,
rectum and colon, and ovary) [25–27]. Most of these studies failed to
look for contamination of mitochondrial DNA by nuclear cytochrome
b pseudogenes [28,29]. Therefore, it would be premature to suggest a
causal relationship between these mutations and cancer, despite
evidence that the resulting protein changes can adversely affect
complex III function [30].
3. Nuclear QP-C gene
To date, no mutations in nuclear genes encoding complex III
subunits have been reported, but a complex rearrangement of the
human QP-C gene (7 modiﬁed amino acids and addition of a 14-amino
acid-long segment at the C terminus) [31]. The QP-C gene encodes the
ubiquinone-binding protein, also known as subunit VII, of complex III
(Fig. 1). That the rearrangement causes disease is suggested by familial
segregation of the abnormalities and by yeast studies establishing a
major role for the terminal helical domain of the QP-C protein in
maintaining or assembling complex III [32]. Surprisingly, although the
rearrangement resulted in severe complex III deﬁciency in the liver,
the patients had no permanent liver dysfunction. They experienced
metabolic crises after fasting and had hepatomegaly, hypoglycaemia,
and mild elevations in liver enzymes [33].
4. Nuclear BCS1L gene
Linkage analysis studies initially identiﬁed mutations affecting the
BCS1L gene in patients with tubulopathy, encephalopathy, and liver
failure [33]; patients with progressive encephalopathy manifesting as
early-onset developmental delay, spasticity, seizures, lactic acidosis,
brain atrophy, and MRI signal changes in the basal ganglia [34]; and
patients with the GRACILE (Growth Retardation, Amino aciduria,
Cholestasis, Iron overload, Lactic acidosis, and Early death) syndrome,
a recessively inherited lethal disease characterized by fetal growth
retardation, lactic acidosis, aminoaciduria, cholestasis, and abnorm-
alities in ironmetabolism [35] (Fig. 3). BCS1L encodes a member of theAAA ATPase family that is required for Rieske iron–sulfur protein
insertion within complex III [36]. In all cases, severe complex III
deﬁciency was noted, accompanied in patients with GRACILE
syndrome with a more generalized dysfunction of the respiratory
chain. In addition, missense mutations in the BCS1L gene cause
Björnstad syndrome, an extremely rare inherited disorder character-
ized by ﬂat twisted hair shafts (pili torti) and sensorineural hearing
loss. Patients with this disorder have dry, fragile, lusterless, and/or
coarse scalp hair, as well as areas of patchy hair loss (alopecia).
Hearing loss is generally bilateral. Autosomal dominant inheritance
and recessive inheritance have both been reported [37]. Interestingly,
all reported BCS1L gene mutations, irrespective of their location and
resulting phenotype, caused impaired respirasome assembly asso-
ciated with increased production of reactive oxygen species [37]. The
variability of the phenotype (multisystem failure versus Björnstad
syndrome) may be related to variable production of these deleterious
oxygen species.
5. Discussion
To date, mutations in only three genes have been identiﬁed in
patients with primary complex III deﬁciencies. Complex III in all
mammals consists of 11 subunits, and an unknown number of gene-
speciﬁc factors and proteins are involved in the translation, chaperoning
and assembly of complex III components (e.g., in yeast, BCS1p, Cbp3p,
and Cbp4p) [38]. Clearly, much remains to be learned about the genetic
underpinnings of complex III deﬁciencies in humans. The considerable
variability in the tissues involved, age at disease onset, and outcome
illustrate the complexity of human mitochondrial disorders [22].
A number of factors may contribute to this complexity. One of
these factors may be variability in the severity of the deﬁciencies [39].
Unfortunately, data from different laboratories are often difﬁcult to
compare, as different assay conditions are used for measuring
respiratory-chain enzyme activities. In most cases, the amount and
nature of available tissues and cells are limited. Thus, skeletal muscle
and cultured ﬁbroblasts are often the only available samples for
studying these diseases that frequently target the nervous system [13].
As a result, the severity of the deﬁciency in clinically affected tissues
from patients is usually unknown. In the case of mitochondrial
cytochrome b mutations, the severity of the deﬁciency is possibly
related to the level of heteroplasmy, which may vary across tissues
[21]. However once again, heteroplasmy is often evaluated in
peripheral tissues, which may not reﬂect the level of heteroplasmy
in the affected tissue. Finally, there may be no simple relationship
between mutant load and disease progression. For example, the
G15498Amutation in cytochrome b, which fulﬁls most of the accepted
criteria for pathogenicity [40] (although it does not lead to an
abnormal phenotype when introduced in the yeast), can remain
clinically silent in homoplasmic carriers [41].
The occurrence of tissue-speciﬁc isoforms has not been reported
for the two nuclear complex III genes in which mutations have been
identiﬁed (BCS1L and QP-C). A longstanding hypothesis involves
speciﬁc sensitivity of each tissue to either mitochondrial ATP
depletion (high energy requirements) [42] or superoxides [43].
Given that complex III is among the main sites of superoxide
production, a key role for superoxides in diseases associated with
complex III deﬁciency is likely, as long as complex III components/
ubiquinone remain in the reduced state. However, deﬁnitive proof
that superoxides play a critical role is still lacking. In particular, if
sensorineural deafness (in patients with Björnstad syndrome) results
from tissue-speciﬁc superoxide sensitivity, sensorineural deafness
would be expected to occur in all patients with complex III deﬁciency.
Similarly, superoxide overproduction may underlie the optic nerve
degeneration seen in LHON, this nerve being exquisitely sensitive to
superoxides [44]. However, optic nerve degeneration is far to be
consistently observed in case of complex III deﬁciency. Identifying the
185P. Bénit et al. / Biochimica et Biophysica Acta 1793 (2009) 181–185deleterious mechanism(s) underlying the various diseases associated
with complex III deﬁciency appears to be of chief importance, since it
may affect our ability to devise therapeutic strategies to counteract
these diseases.
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